CU23792A3 - Novedosos anticuerpos antiproliferación - Google Patents

Novedosos anticuerpos antiproliferación

Info

Publication number
CU23792A3
CU23792A3 CU20090082A CU20090082A CU23792A3 CU 23792 A3 CU23792 A3 CU 23792A3 CU 20090082 A CU20090082 A CU 20090082A CU 20090082 A CU20090082 A CU 20090082A CU 23792 A3 CU23792 A3 CU 23792A3
Authority
CU
Cuba
Prior art keywords
antibodies
new
present
antiproliferation antibodies
antiproliferation
Prior art date
Application number
CU20090082A
Other languages
English (en)
Spanish (es)
Inventor
Cedric Bes
Jean-Francois Haeuw
Nathalie Corvaia
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CU23792A3 publication Critical patent/CU23792A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CU20090082A 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferación CU23792A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
CU23792A3 true CU23792A3 (es) 2012-03-15

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090082A CU23792A3 (es) 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferación

Country Status (27)

Country Link
US (2) US8071730B2 (enExample)
EP (1) EP2074148A1 (enExample)
JP (1) JP2010509931A (enExample)
KR (1) KR20090088878A (enExample)
CN (1) CN101535344B (enExample)
AU (1) AU2007324509B2 (enExample)
BR (1) BRPI0719323A2 (enExample)
CA (1) CA2670039A1 (enExample)
CL (1) CL2007003357A1 (enExample)
CR (1) CR10788A (enExample)
CU (1) CU23792A3 (enExample)
EC (1) ECSP099341A (enExample)
FR (1) FR2909092B1 (enExample)
GE (1) GEP20125629B (enExample)
GT (1) GT200900126A (enExample)
IL (1) IL198744A0 (enExample)
MA (1) MA30891B1 (enExample)
MX (1) MX2009005293A (enExample)
NI (1) NI200900079A (enExample)
NO (1) NO20092360L (enExample)
NZ (1) NZ576174A (enExample)
RU (1) RU2451689C2 (enExample)
SA (1) SA07280637B1 (enExample)
TN (1) TN2009000194A1 (enExample)
TW (1) TW200829602A (enExample)
UA (1) UA99602C2 (enExample)
WO (1) WO2008062063A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
US8802827B2 (en) * 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
US8790649B2 (en) * 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
EP3489261B1 (en) 2012-08-24 2020-10-21 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
JP6966176B2 (ja) * 2016-03-01 2021-11-10 イサム リサーチ ディベロップメント カンパニー オブ ザ ヘブルー ユニバーシティ オブ エルサレム エルティーディー． ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
MY196869A (en) 2016-06-27 2023-05-05 Univ California Cancer treatment combinations
BR112019002127A2 (pt) * 2016-08-03 2019-09-17 Nextcure Inc proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
SK14812000A3 (sk) * 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
PL207994B1 (pl) * 1999-03-11 2011-02-28 Serono Lab Polipeptyd, skierowane przeciw niemu przeciwciało i ich zastosowanie w medycynie oraz kodujące go poli- lub oligonukleotydy
EP1708961B1 (en) * 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
WO2007127476A2 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
FR2909092A1 (fr) 2008-05-30
UA99602C2 (ru) 2012-09-10
AU2007324509A1 (en) 2008-05-29
KR20090088878A (ko) 2009-08-20
AU2007324509B2 (en) 2013-01-17
NI200900079A (es) 2010-11-10
JP2010509931A (ja) 2010-04-02
TW200829602A (en) 2008-07-16
MA30891B1 (fr) 2009-11-02
GEP20125629B (en) 2012-09-10
HK1132752A1 (en) 2010-03-05
ECSP099341A (es) 2009-06-30
GT200900126A (es) 2011-09-02
CL2007003357A1 (es) 2008-04-04
CA2670039A1 (en) 2008-05-29
US8071730B2 (en) 2011-12-06
SA07280637B1 (ar) 2012-04-11
EP2074148A1 (en) 2009-07-01
BRPI0719323A2 (pt) 2014-02-04
IL198744A0 (en) 2010-02-17
RU2451689C2 (ru) 2012-05-27
CN101535344B (zh) 2013-10-16
US20120156191A1 (en) 2012-06-21
CR10788A (es) 2009-06-23
FR2909092B1 (fr) 2012-10-19
NO20092360L (no) 2009-08-11
US20100092455A1 (en) 2010-04-15
NZ576174A (en) 2012-03-30
TN2009000194A1 (en) 2010-10-18
MX2009005293A (es) 2009-08-07
WO2008062063A1 (en) 2008-05-29
CN101535344A (zh) 2009-09-16
RU2009123409A (ru) 2010-12-27

Similar Documents

Publication Publication Date Title
NI200900079A (es) Novedosos anticuerpos antiproliferación.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
MX2019013655A (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
GT200500237A (es) Derivados de pirimidina
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX2007014132A (es) Compuestos de diarilhidantoina.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
EA201390010A1 (ru) Замещенные триазолопиридины
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)